WO1999058978A3 - Tumour markers - Google Patents

Tumour markers Download PDF

Info

Publication number
WO1999058978A3
WO1999058978A3 PCT/GB1999/001479 GB9901479W WO9958978A3 WO 1999058978 A3 WO1999058978 A3 WO 1999058978A3 GB 9901479 W GB9901479 W GB 9901479W WO 9958978 A3 WO9958978 A3 WO 9958978A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour marker
antigens
sample
immune response
cancer
Prior art date
Application number
PCT/GB1999/001479
Other languages
French (fr)
Other versions
WO1999058978A2 (en
Inventor
John Forsyth Russell Robertson
Catherine Rosamund Loui Graves
Michael Rawling Price
Original Assignee
Univ Nottingham
John Forsyth Russell Robertson
Catherine Rosamund Loui Graves
Michael Rawling Price
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10831824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999058978(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE69929185T priority Critical patent/DE69929185T2/en
Priority to SI9930885T priority patent/SI1078264T1/en
Priority to AU38388/99A priority patent/AU3838899A/en
Priority to US09/700,092 priority patent/US7402403B1/en
Priority to AT99921014T priority patent/ATE314651T1/en
Application filed by Univ Nottingham, John Forsyth Russell Robertson, Catherine Rosamund Loui Graves, Michael Rawling Price filed Critical Univ Nottingham
Priority to EP99921014A priority patent/EP1078264B1/en
Publication of WO1999058978A2 publication Critical patent/WO1999058978A2/en
Publication of WO1999058978A3 publication Critical patent/WO1999058978A3/en
Priority to US11/953,237 priority patent/US8114604B2/en
Priority to US13/349,348 priority patent/US9696319B2/en
Priority to US13/438,344 priority patent/US20130090251A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Abstract

A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigens. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
PCT/GB1999/001479 1998-05-11 1999-05-11 Tumour markers WO1999058978A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP99921014A EP1078264B1 (en) 1998-05-11 1999-05-11 Tumour markers
SI9930885T SI1078264T1 (en) 1998-05-11 1999-05-11 Tumour markers
AU38388/99A AU3838899A (en) 1998-05-11 1999-05-11 Tumour markers
US09/700,092 US7402403B1 (en) 1998-05-11 1999-05-11 Tumour markers
AT99921014T ATE314651T1 (en) 1998-05-11 1999-05-11 TUMOR MARKERS
DE69929185T DE69929185T2 (en) 1998-05-11 1999-05-11 TUMOR MARKER
US11/953,237 US8114604B2 (en) 1998-05-11 2007-12-10 Tumour markers
US13/349,348 US9696319B2 (en) 1998-05-11 2012-01-12 Tumour markers
US13/438,344 US20130090251A1 (en) 1998-05-11 2012-04-03 Tumour Markers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9810040.7 1998-05-11
GBGB9810040.7A GB9810040D0 (en) 1998-05-11 1998-05-11 Blood borne tumour markers

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/700,092 A-371-Of-International US7402403B1 (en) 1998-05-11 1999-05-11 Tumour markers
US11/953,237 Continuation US8114604B2 (en) 1998-05-11 2007-12-10 Tumour markers
US11/953,237 Continuation-In-Part US8114604B2 (en) 1998-05-11 2007-12-10 Tumour markers

Publications (2)

Publication Number Publication Date
WO1999058978A2 WO1999058978A2 (en) 1999-11-18
WO1999058978A3 true WO1999058978A3 (en) 2000-01-20

Family

ID=10831824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001479 WO1999058978A2 (en) 1998-05-11 1999-05-11 Tumour markers

Country Status (12)

Country Link
US (4) US7402403B1 (en)
EP (3) EP1078264B1 (en)
AT (1) ATE314651T1 (en)
AU (1) AU3838899A (en)
CY (1) CY1115366T1 (en)
DE (1) DE69929185T2 (en)
DK (2) DK1731619T3 (en)
ES (2) ES2443096T3 (en)
GB (1) GB9810040D0 (en)
PT (2) PT1078264E (en)
SI (1) SI1078264T1 (en)
WO (1) WO1999058978A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20040072264A1 (en) * 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
WO2003065042A1 (en) * 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US7214498B2 (en) 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20050221305A1 (en) * 2001-11-09 2005-10-06 Benaroya Research Institute At Virginia Mason Antigen panels and methods of using the same
DK1529060T3 (en) * 2002-07-22 2014-12-15 Glycotope Gmbh PROCEDURE FOR PREPARING AN IMMUNSTIMULATORY MUCIN (MUC1)
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
EP1723429A1 (en) * 2004-03-08 2006-11-22 The United States of America as represented by The Secretary, Department of Health and Human Services National Institutes of Health Autoantibody detection for cancer diagnostics
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
SE0402536D0 (en) * 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
PT1889059E (en) 2005-05-27 2009-10-01 Oncimmune Ltd Improved immunoassay methods
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
WO2006132587A1 (en) * 2005-06-10 2006-12-14 Forskarpatent I Syd Ab Tumour marker in brca2 associated breast cancer
KR20080073740A (en) * 2005-11-10 2008-08-11 유니버시티 오브 캔터키 Lung cancer diagnostic assay
JP2009541259A (en) * 2006-06-20 2009-11-26 ブラッコ・イメージング・ソシエタ・ペル・アチオニ Method for producing specific antibody against saccharide antigen
EP2041569A4 (en) * 2006-07-08 2009-11-18 Univ Kentucky Res Found Lung cancer diagnostic assay
EP2062053B1 (en) * 2006-09-13 2012-12-05 Oncimmune LTD Improved immunoassay methods
GB2441824A (en) * 2006-09-13 2008-03-19 Oncimmune Ltd Immunoassay method
CN101632020B (en) 2006-09-13 2013-11-27 昂西免疫有限公司 Improved immunoassay methods
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
WO2010125566A2 (en) 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
KR20120098992A (en) 2009-06-23 2012-09-06 이벤투스 디아그노스틱스 이스라엘 리미티드 A method and system for the detection of cancer
US20130189707A1 (en) * 2010-01-26 2013-07-25 Svetlana Alexandrovna Sergeeva Method of determination of autoantibody level by means of enzyme immunoassay
EP2548025A4 (en) 2010-03-17 2013-09-25 Univ Michigan Using phage epitopes to profile the immune response
WO2011120015A2 (en) * 2010-03-26 2011-09-29 Armune Biosciences, Inc. Method and system of particle-coupled phage epitope
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
JP6603009B2 (en) 2010-08-13 2019-11-06 アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティ Method for assisting detection of breast cancer and polypeptide probe set for breast cancer detection
US20130040839A1 (en) * 2011-06-27 2013-02-14 Ambergen, Inc. Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
BR112017003310A2 (en) 2014-08-18 2018-01-23 Basf Se polyester modified polybutadienols for producing polyurethane elastomers and thermoplastic polyurethanes
US9689874B2 (en) 2015-04-10 2017-06-27 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20210132061A1 (en) * 2017-04-14 2021-05-06 The Regents Of The University Of California Methods and Devices for Performing Auto-Antibody Assays
CN109448790B (en) * 2018-11-19 2021-11-09 上海科技大学 Storage medium, equipment and device for determining tumor immunotherapy marker
WO2022013321A2 (en) 2020-07-14 2022-01-20 Oncimmune Limited Antibody assay
GB2600701A (en) 2020-11-04 2022-05-11 Oncimmune Ltd Antibody assay
CN112345755B (en) * 2020-09-23 2023-06-16 杭州凯保罗生物科技有限公司 Biomarker for breast cancer and application thereof
WO2023091714A1 (en) * 2021-11-18 2023-05-25 Greenwich Lifesciences, Inc. Methods for assessing an immune response and predicting cancer recurrence and assessment of current and prior cancer status
GB2622246A (en) 2022-09-08 2024-03-13 Oncimmune Germany Gmbh Antibody assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023728A1 (en) * 1993-04-16 1994-10-27 Northwestern University Immunogenic cancer proteins and peptides and method of use
JPH09189702A (en) * 1996-01-09 1997-07-22 Hitachi Chem Co Ltd Method for measuring antimucin antibody, cancer measuring method, and cancer diagnostic medicine

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241044A (en) 1978-12-28 1980-12-23 Abbott Laboratories Method of diagnosing cancer by detecting elevated anti-T antibody activity
NZ211453A (en) * 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
DE3685818T2 (en) 1986-03-10 1993-01-14 Imre Corp IMMUNE COMPLEX TEST PROCEDURE.
WO1989001153A1 (en) 1987-07-24 1989-02-09 Xoma Corporation Methods for breast cancer detection
US4937185A (en) 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5157020A (en) 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
DK9091D0 (en) 1991-01-18 1991-01-18 Novo Nordisk As PROCEDURE FOR MANUFACTURING ANTIBODIES
DE4120412C1 (en) 1991-06-20 1993-01-07 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6322989B1 (en) * 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5747268A (en) 1993-04-22 1998-05-05 Dade International Inc. Tumor marker control
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5721105A (en) 1994-02-20 1998-02-24 B.R.A.H.M.S. Diagnostica Gmbh Method for the immunological determination of proteins and kit for carrying out the method
JPH07294530A (en) 1994-04-20 1995-11-10 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk Detection of antibody in body fluids against pathogn
CA2148971A1 (en) 1994-05-26 1995-11-27 Izak Bahar Calibrator matrix
JPH10505819A (en) 1994-06-24 1998-06-09 ヴラディミール ピー． トーチリン Use of autoantibodies for treatment and prevention of tumors
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5561049A (en) 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
JPH09229933A (en) 1996-02-27 1997-09-05 Kokichi Sugano Autoantibody detecting method for p53 protein
JP2001517206A (en) * 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン Melanoma cell lines expressing immunodominant shared melanoma antigens and methods of use thereof
WO1998055872A1 (en) * 1997-06-03 1998-12-10 Amdl, Inc. Immunoassay for the detection of cancer
DE19805815C1 (en) 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostic for the detection of autoimmune hepatitis
JP4083855B2 (en) 1998-02-16 2008-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Lung cancer prognosis test method
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
AUPP349098A0 (en) 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
FR2780161B1 (en) 1998-06-17 2000-09-29 Centre Nat Rech Scient METHOD FOR EARLY DIAGNOSIS OF CANCER BASED ON THE SEARCH FOR AUTO-ANTIBODIES DIRECTED AGAINST THE CSK PROTEIN AND KIT FOR ITS IMPLEMENTATION
CA2349593A1 (en) 1998-11-05 2000-05-11 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
US6387639B1 (en) * 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US7807810B2 (en) 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030138860A1 (en) 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
EP1354206A2 (en) 2000-12-13 2003-10-22 Bio-Rad Laboratories, Inc. Standard diluent for multiplex assays
CA2451045A1 (en) 2001-06-21 2003-09-04 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
US20030049692A1 (en) 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US7283245B2 (en) * 2004-01-20 2007-10-16 General Electric Company Handheld device with a disposable element for chemical analysis of multiple analytes
JP2005352771A (en) * 2004-06-10 2005-12-22 Hitachi Software Eng Co Ltd Pattern recognition system by expression profile
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
WO2007032634A1 (en) * 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University A method for production of mature natural killer cell
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
CN101632020B (en) 2006-09-13 2013-11-27 昂西免疫有限公司 Improved immunoassay methods
EP2062053B1 (en) 2006-09-13 2012-12-05 Oncimmune LTD Improved immunoassay methods
US7586970B2 (en) * 2007-02-23 2009-09-08 Alfalight, Inc. High efficiency partial distributed feedback (p-DFB) laser
GB0725239D0 (en) 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023728A1 (en) * 1993-04-16 1994-10-27 Northwestern University Immunogenic cancer proteins and peptides and method of use
JPH09189702A (en) * 1996-01-09 1997-07-22 Hitachi Chem Co Ltd Method for measuring antimucin antibody, cancer measuring method, and cancer diagnostic medicine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GÜRE ET AL: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3", CANCER RESEARCH, vol. 58, no. 58, 1 March 1998 (1998-03-01), pages 1034 - 1041 41, XP002103188, ISSN: 0008-5472 *
MERCER D W: "USE OF MULTIPLE MARKERS TO ENHANCE CLINICAL UTILITY", IMMUNOLOGY SERIES, vol. 53, 1 January 1990 (1990-01-01), pages 39 - 54, XP000576588 *
PATENT ABSTRACTS OF JAPAN vol. 097, no. 011 28 November 1997 (1997-11-28) *
PETRAKOU, EFTICHIA (1) ET AL: "Preliminary studies on the binding of human autoantibodies to the MUC1 antigen.", INTERNATIONAL JOURNAL OF ONCOLOGY, (1997) VOL. 11, NO. SUPPL., PP. 902. MEETING INFO.: 2ND WORLD CONGRESS ON ADVANCES IN ONCOLOGY ATHENS, GREECE OCTOBER 16-18, 1997, XP002115790 *
SAHIN ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, 1 December 1995 (1995-12-01), pages 11810 - 11813, XP002091914, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU3838899A (en) 1999-11-29
US20120115749A1 (en) 2012-05-10
EP1710253A3 (en) 2007-10-31
DE69929185D1 (en) 2006-02-02
CY1115366T1 (en) 2017-01-04
PT1731619E (en) 2014-03-10
US8114604B2 (en) 2012-02-14
EP1710253A2 (en) 2006-10-11
ES2443096T3 (en) 2014-02-17
ES2257048T3 (en) 2006-07-16
EP1731619A3 (en) 2007-09-26
EP1078264A2 (en) 2001-02-28
SI1078264T1 (en) 2006-06-30
GB9810040D0 (en) 1998-07-08
PT1078264E (en) 2006-05-31
DE69929185T2 (en) 2006-08-31
DK1731619T3 (en) 2014-03-24
EP1078264B1 (en) 2005-12-28
US7402403B1 (en) 2008-07-22
US20080153113A1 (en) 2008-06-26
WO1999058978A2 (en) 1999-11-18
EP1731619A2 (en) 2006-12-13
ATE314651T1 (en) 2006-01-15
US9696319B2 (en) 2017-07-04
US20130090251A1 (en) 2013-04-11
EP1731619B1 (en) 2013-12-18
DK1078264T3 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
WO1999058978A3 (en) Tumour markers
CA2384579A1 (en) Early cancer tumor marker
AU1671300A (en) Cancer detection method and reagents
AU1674400A (en) Kidney disease detection and treatment
Edwards et al. Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer.
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
CA2164498A1 (en) Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
WO1995016919A3 (en) Methods and compositions for the detection of colon cancers
CA2214488A1 (en) Determination of cpsa
Shimizu et al. Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis
WO2004112570A3 (en) Detection of survivin in the biological fluids of cancer patients
WO2000026668A3 (en) S100 proteins and autoantibodies as serum markers for cancer
AU3117289A (en) A method for early detection of lung cancer
WO1991019195A3 (en) Method for detecting and/or assaying hormones and antibodies for use in said method
EP0974841A3 (en) Suppression of interference in immunoassays using substances derived from the framework regions of antibodies
EP0226888A3 (en) Monoclonal antibodies specific to galactosyltransferase isoenzyme ii and their use in cancer immunoassays
AU2353188A (en) A diagnostic agent and a method for the determination of apolipoprotein b
CA2294514A1 (en) Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum
EP0204922A3 (en) Immunohistochemical assay for detection of a tumor-associated marker (p53)
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
ATE135468T1 (en) PRE-TESTING OF PROSTATE CANCER BY SERUM PROSTATIC SPECIFIC ANTIGEN
WO2000060119A3 (en) Methods for detecting cancer cells
WO2002071065A8 (en) Immunological detection of prostate diseases and prostasome-related conditions
CA2264963A1 (en) Protein markers for esophageal cancer
WO2004016065A3 (en) Immunochromatography system and method for the simultaneous identification of aga and t-tg antibodies and use thereof for the diagnosis of celiac disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999921014

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999921014

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09700092

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1999921014

Country of ref document: EP